Archive - Latest News Search Engine - Global and Local Breaking News

SEEKING DOGS WITH EXTREME FEAR OF THUNDERSTORMS FOR VETERINARY STUDY IN FLORIDA

SEEKING DOGS WITH EXTREME FEAR OF THUNDERSTORMS FOR VETERINARY STUDY IN FLORIDA

The Center Origin Conducts Colorado's First Regulated High-Dose Psilocybin Session

The Center Origin Conducts Colorado's First Regulated High-Dose Psilocybin Session

News24 | Zuma hits out at ex-SGs; More City Power ‘wastage’ exposed: Today’s top 7 stories in 7 minutes

News24 | Zuma hits out at ex-SGs; More City Power ‘wastage’ exposed: Today’s top 7 stories in 7 minutes

Foresee Pharmaceuticals announces reaching a significant milestone, of complete enrollment of its Phase 3 Casppian trial for patients with Central Precocious Puberty (CPP)

Foresee Pharmaceuticals announces reaching a significant milestone, of complete enrollment of its Phase 3 Casppian trial for patients with Central Precocious Puberty (CPP)

Your briefing

SEEKING DOGS WITH EXTREME FEAR OF THUNDERSTORMS FOR VETERINARY STUDY IN FLORIDA

Multiple Clinics Participating in Study Evaluating an Investigational Medication With the Goal of Achieving the Medication's Approval by FDA RALEIGH, ...

SEEKING DOGS WITH EXTREME FEAR OF THUNDERSTORMS FOR VETERINARY STUDY IN FLORIDA

The Center Origin Conducts Colorado's First Regulated High-Dose Psilocybin Session

DENVER, June 17, 2025 /PRNewswire/ -- The Center Origin, a licensed natural medicine healing center operating under Colorado's newly launched Natural ...

The Center Origin Conducts Colorado's First Regulated High-Dose Psilocybin Session

News24 | Zuma hits out at ex-SGs; More City Power ‘wastage’ exposed: Today’s top 7 stories in 7 minutes

News24 brings you the top stories of the day, summarised into neat little packages. Read through quickly or listen to the articles via our customised ...

News24 | Zuma hits out at ex-SGs; More City Power ‘wastage’ exposed: Today’s top 7 stories in 7 minutes

Foresee Pharmaceuticals announces reaching a significant milestone, of complete enrollment of its Phase 3 Casppian trial for patients with Central Pre...

A multicenter, multinational Phase 3 Casppian study will evaluate the efficacy and safety of leuprolide mesylate (FP-001) 42 mg controlled-release in ...

Foresee Pharmaceuticals announces reaching a significant milestone, of complete enrollment of its Phase 3 Casppian trial for patients with Central Precocious Puberty (CPP)